# ACIP Recommended Adult Immunization Schedule â€” United States, 2025

## Metadata
- **Specialty**: Preventive Medicine, Immunization
- **Organization**: Advisory Committee on Immunization Practices (ACIP), CDC
- **Year**: 2025
- **PMID**: [39820474](https://pubmed.ncbi.nlm.nih.gov/39820474/)
- **Source URL**: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html

## Scope
Consolidated summary of ACIP recommendations for adult vaccination (ages 19 years and older).

## Key Changes for 2025

### Influenza
- Changed from quadrivalent to **trivalent formulation** per FDA approval for 2024-25 season
- Age 19+: 1 dose annually of age-appropriate vaccine
- Age 65+: Prefer HD-IIV3, RIV3, or aIIV3; use any age-appropriate vaccine if preferred not available

### RSV (Respiratory Syncytial Virus)
- **Age 60+**: Single dose of Arexvy, Abrysvo, or mResvia
- **Age 50-59 at increased risk**: May receive single dose
- Best administered late summer/early fall (August-October)
- Additional doses not recommended

### Pneumococcal Vaccines
- Not previously received PCV13/PCV15/PCV20/PCV21: 1 dose PCV15, PCV20, or PCV21
- If PCV15 used: Administer PPSV23 at least 1 year after

### COVID-19
- Updated recommendations for current vaccine formulations
- See current CDC guidance for specific product recommendations

### Meningococcal Serogroup B
- Updated recommendations based on risk factors

### Other Updates
- **Hepatitis B (HepB)**: Clarifications in notes
- **Mpox**: Clarifications in notes
- **Tdap**: Clarifications in notes
- **Inactivated Polio Vaccine**: Added to tables

## Routine Adult Vaccines

| Vaccine | Ages 19-26 | Ages 27-49 | Ages 50-64 | Ages 65+ |
|---------|------------|------------|------------|----------|
| Influenza | Annual | Annual | Annual | Annual (prefer high-dose) |
| Tdap/Td | 1 Tdap, then Td every 10y | Td every 10y | Td every 10y | Td every 10y |
| MMR | 1-2 doses if not immune | 1-2 doses if not immune | - | - |
| Varicella | 2 doses if not immune | 2 doses if not immune | - | - |
| Zoster (RZV) | - | - | 2 doses | 2 doses |
| HPV | Through age 26 | Shared decision 27-45 | - | - |
| Pneumococcal | Risk-based | Risk-based | Risk-based | 1 dose PCV + PPSV23 |
| RSV | - | - | Risk-based 50-59 | 1 dose 60+ |

## Resources
- Full schedule: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
- Individual vaccine recommendations: https://www.cdc.gov/acip-recs/hcp/vaccine-specific/index.html
